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Abstract 
Purpose: The prognosis for recipients with hepatocellular carcinoma (HCC) of salvage liver transplantation (SLT) ver-
sus those of primary liver transplantation (PLT) remains controversial. The objective of this study was to evaluate the 
clinical features and survival rate of SLT recipients.
Methods: Three hundred seventy-one patients with HCC transplanted at Shanghai General Hospital, China, between 
October 2001 and October 2011 were separated into PLT (n = 295) and SLT (n = 76) groups. Patient characteristics 
and survival curves were studied by univariate and multivariate analysis. A Milan criteria-stratified survival analysis was 
conducted.
Results: The proportions of reoperation (11.8 vs. 5.4 %, P = 0.047) and early postoperative mortality (11.8 vs. 4.7 %, 
P = 0.032) were higher in the SLT group than in the PLT group. Recurrence free survival (RFS) rate and overall survival 
(OS) rate had no statistically significant differences after stratification using Milan criteria between the PLT group and 
SLT group. Alphafetoprotein >400 ng/mL (P = 0.011), microscopic vascular invasion (MVI) (P < 0.001), tumor node 
metastasis (TNM) staging (P = 0.006), and out of Milan criteria (P < 0.001) were independent risk factors for RFS, while 
MVI (P < 0.001), TNM staging (P = 0.009), and out of Milan criteria (P = 0.003) were factors for OS. In the multivariate 
logistic regression analysis, HCC recurrence was associated with MVI (OR = 4.196 [2.538–6.936], P < 0.001), and out of 
Milan criteria (OR = 2.704 [1.643–4.451], P < 0.001).
Conclusions: Our retrospective, single-center study demonstrated that SLT increases surgical difficulty; however, it 
has good post-transplantation OS and is a feasible alternative after HCC recurrence within Milan criteria.
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Background
Hepatocellular carcinoma (HCC) is the seventh 
most common cancer and the third leading cause of 
cancer-related death worldwide (Yang and Roberts 
2010), with an estimated 782,000 liver cancer cases 
and 746,000 liver cancer-related deaths in 2012 (Siegel 
et  al. 2014). In general, HCC incidence and mortality 
have been slowly decreasing in previous areas of rela-
tively high incidence, including China and Japan; most 
HCC cases (>80  %) now occur in sub-Saharan Africa 
and in Eastern Asia, with typical incidence rates of >20 
per 100,000 individuals (El-Serag 2012). Despite vari-
ous therapeutic options, such as liver resection (LR), 
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radiofrequency ablation, and transcatheter hepatic 
arterial chemoembolization, the prognosis remains 
generally poor, leading to 500,000 deaths per year 
(Maluccio and Covey 2012).
Liver transplantation (LT) is advisable in patients with 
HCC and decompensated cirrhosis with excellent results 
in terms of overall and recurrence-free survival (OS and 
RFS, respectively) in selected patients (Mazzaferro et al. 
1996; Befeler et al. 2005; Lee et al. 2010); however, organ 
shortage is a worldwide problem, especially in China, 
because of the large population base, people’s financial 
situation, and legal limitations. As a result, the risk of 
drop-out for tumor progression and the deterioration of 
the patients’ clinical conditions are an ongoing problem 
(Yao et al. 2002, 2004; Guerrini et al. 2009; Freeman et al. 
2006; Li and Neuberger 2009).
Salvage liver transplantation (SLT) is a protocol that 
offers LR first and subsequent liver transplantation for 
tumor recurrence or deteriorating liver function (Majno 
et  al. 2000). For patients with small, solitary HCC and 
with preserved hepatic function, it has been reported that 
SLT has a long-term survival rate similar to that of those 
who directly undergo primary liver transplantation (PLT) 
(Majno et al. 2000; Cherqui et al. 2009; Wu et al. 2012; Hu 
et al. 2012). SLT, which reduces the risk of HCC progress-
ing during the time awaiting transplantation, might offer 
a good strategy for relieving patients with a good progno-
sis and also alleviate the burden on the donor organ pool 
(Wu et al. 2012; Fan et al. 2011).
Our institution (Shanghai General Hospital) adopted 
and conducted SLT strategy since it was first proposed 
by Majno et al. (2000). To aid in the assessment of the 
feasibility of SLT and its indications, we retrospec-
tively reviewed and compared the clinical features and 
survival rates of patients undergoing SLT with those 
undergoing PLT in our institution between 2001 and 
2011.
Results
Clinical demographics and follow up data
The main demographics of the 371 patients are listed 
in Table  1. The PLT group had a significantly higher 
percentage of alphafetoprotein (AFP)  >400  ng/mL 
(P = 0.008) than the SLT group. Moreover, the percentage 
of patients with Child–Pugh B, C was higher in the PLT 
group than in the SLT group (P =  0.002). Tumor char-
acteristics and operating parameters between the two 
groups are listed in Table  2. The percentage of patients 
with the largest tumor >3.0 cm in diameter (P < 0.001), 
microscopic vascular invasion (MVI) (P  =  0.001), or 
recurrence (P  <  0.001) were higher in the PLT group, 
while that of multinodular tumors was lower (P = 0.018). 
Moreover, there were more patients with noncompliance 
with Milan criteria in the PLT group, but the difference 
was not significant (P > 0.05). Among operating param-
eters, the proportion of reoperation (11.8 vs. 5.4  %, 
respectively; P = 0.047) and early postoperative mortal-
ity (11.8 vs. 4.7  %, respectively; P =  0.032) were higher 
in SLT group than in the PLT group, which indicated 
that SLT might increase surgical difficulty and risk. The 
mean and median follow-up time was 32.43 months and 
19.53  months, respectively (range 0.03–146.60  months). 
The 1-, 3- and 5-year survival rates were 69.2, 51.8 and 
46.6 %, respectively. One hundred seventy-eight (48.0 %) 
patients died during follow-up. The most common cause 
of death in these patients was HCC recurrence.
Patient survival: Kaplan–Meier survival curves and Cox 
hazard regression analysis
Recurrence-free survival and OS between the SLT and 
PLT groups were analyzed with Kaplan–Meier survival 
estimates as well as the log-rank test. Interestingly, the 
RFS rate, but not the OS rate, was significantly lower in 
the PLT group (Fig. 1a, P < 0.001 and Fig. 1b, P > 0.05, 
respectively). Univariate and multivariate models were 
used to identify factors associated with RFS and OS 
for all LT patients. All variables with P  <  0.05 in the 
univariate analysis (data not shown) were placed into 
the multivariate Cox regression model. As shown in 
Table 3, AFP >400 ng/mL (P = 0.011), MVI (P < 0.001), 
Table 1 Demographics of the patients
PLT primary liver transplantation, SLT salvage liver transplantation, MELD model 
for end-stage liver disease, AFP alpha-fetoprotein, HBV hepatitis B virus, HCV, 















11.0 ± 4.4 10.6 ± 5.8 0.570
AFP >400 ng/mL, 
no (%)
101 (34.2) 14 (18.4) 0.008
Underlying liver disease, no (%)
 HBV 277 (93.9) 68 (89.5)




 Wilson’s disease 1 (0.3) 0 (0)
 Chronic alcohol-
ism
2 (0.7) 0 (0)
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tumor-node-metastasis (TNM) staging (P =  0.006), and 
noncompliance with Milan criteria (P  <  0.001) were 
independent risk factors for RFS, while MVI (P < 0.001), 
TNM staging (P = 0.009), and noncompliance with Milan 
criteria (P = 0.003) were risk factors for OS.
In consideration of the results of multivariate analysis, 
and more patients with the largest tumor being >3.0 cm 
in diameter, MVI, and noncompliance with Milan criteria 
in the PLT group, a Milan criteria-stratified survival anal-
ysis was conducted. Among the 371 patients, 131 (35.3 %) 
met the Milan criteria—101 (34.2  %) in the PLT group 
and 30 (39.5  %) in the SLT group. As shown in Fig.  2, 
there were no statistically significant differences in either 
RFS or OS between the SLT and PLT groups (P = 0.193 
and P = 0.414, respectively; Fig. 2a, b).
Risk factors of recurrence: multivariate logistic regression 
analysis
Univariate and multivariate models were used to calcu-
late the factors associated with HCC recurrence for all 
LT patients. All variables with P < 0.05 in the univariate 
analysis (data not shown) were put into the multivari-
ate logistic regression model. In the multivariate logistic 
regression analysis, HCC recurrence was significantly 
associated with the following factors: MVI (odds ratio 
[OR] = 4.196 [2.538–6.936], P < 0.001) and noncompli-
ance with Milan criteria (OR  =  2.704 [1.643–4.451], 
P < 0.001) (Table 4). SLT or PLT itself was not an inde-
pendent risk factor of HCC recurrence.
Discussion
Whether SLT and PLT recipients have a similar prog-
nosis remains controversial. In our single-center retro-
spective study, we demonstrated that OS and RFS of SLT 
recipients was not different from those of PLT recipients 
within Milan criteria, even though SLT increases surgical 
difficulties and risks.
Hepatocellular carcinoma is one of the most common 
cancers in China, with a relatively high mortality (El-
Serag 2012). Theoretically, LT is the most effective option 
for HCC because it not only radically removes the tumor 
but also cures the underlying hepatic disease (Befeler 
et al. 2005); however, the shortage of organs greatly limits 
the application of LT to all patients. SLT, raised by Majno 
et al. (2000), might relieve disease progression in patients 
waiting for LT and could reduce the number of trans-
plantations required (Chan et al. 2014).
The outcome for recipients of SLT has been studied 
for many years since it was first proposed in 2000. Some 
studies have indicated that SLT has a prognosis similar 
to that of PLT (Majno et  al. 2000; Cherqui et  al. 2009; 
Wu et al. 2012; Hu et al. 2012), while others have yielded 
contradictory findings (Adam et al. 2003; Guerrini et al. 
2014). In the study conducted by Adam et al. (2003), the 
poor prognosis after SLT compared to that of PLT might 
be related to the relatively higher surgical mortality and 
intraoperative bleeding because of more technical dif-
ficulties in secondary LT. Moreover, only 17 patients 
with HCC recurrence were included in the SLT group. 
Another recent study conducted by Guerrini (2014) dem-
onstrated that SLT achieved good post-transplantation 
survival, but the outcome of SLT remains inferior to PLT 
in the intention-to-treat analysis. RFS and OS between 
SLT and PLT in their study showed no significant differ-
ences, which is consistent with our results.
An interesting observation from this study is that 
the RFS rate was significantly lower in the PLT group 
(Fig. 1a). The explanation for this might be that the PLT 
group in our study appeared to have had more aggres-
sive HCC, as indicated by the greater proportion of 
Table 2 Tumor characteristics and operative parameters
PLT primary liver transplantation, SLT salvage liver transplantation, TNM tumor node metastasis, MVI microscopic vascular invasion
PLT group (n = 295) SLT group (n = 76) P value
Diameter of largest tumor >3 cm, no (%) 189 (64.1) 30 (39.5) <0.001
Multinodular, no (%) 126 (42.7) 44 (57.9) 0.018
TNM staging, (1–2/3–4) 155/140 36/40 0.442
Out of Milan criteria, no (%) 194 (65.8) 46 (60.5) 0.394
Poorly differentiated tumor, no (%) 56 (19.0) 15 (19.7) 0.882
MVI, no (%) 155 (52.5) 24 (31.6) 0.001
Operative time, hour 6.0 ± 2.0 7.0 ± 2.5 0.260
Blood loss, mL 2010 ± 1500 2450 ± 2375 0.052
Packed red cell transfusion, U 8.0 ± 10.0 8.5 ± 8.8 0.078
Reoperation, no (%) 16 (5.4) 9 (11.8) 0.047
Early postoperative mortality, no (%) 14 (4.7) 9 (11.8) 0.032
Recurrence, no (%) 124 (42.0) 10 (13.2) <0.001
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tumors  >3.0  cm in diameter, MVI, and recurrence. 
Accordingly, a Milan criteria-stratified survival analy-
sis was conducted and the results showed no signifi-
cant differences between SLT and PLT, which indicated 
that SLT for HCC recurrence after liver resection is a 
feasible alternative and does not significantly impair 
survival compared to that of PLT. Some studies have 
demonstrated that SLT increases surgical difficulty (Wu 
et al. 2012; Hu et al. 2012). In our study, the SLT group 
did have a remarkably higher proportion of subsequent 
surgery and early postoperative mortality, and with 
longer operative time, more blood loss, and packed red 
cell transfusions, although the differences were not sig-
nificant. Peritoneal adhesions caused by previous upper 
abdominal surgery were the main reason for increased 
surgical difficulty. The adhesions usually occur near the 
intestine and the omentum, according to our experience 
and previous study, and can be reduced by laparoscopic 
surgery (Wu et al. 2012). We believe that the reoperation 
rate and early postoperative mortality can be reduced by 
an accumulation of clinician experience as the number of 
SLT cases increases. In the Cox hazard regression analy-
sis and multivariate logistic regression analysis, MVI was 
an independent risk factor for RFS, OS, and recurrence, 
but SLT or PLT was not. However, the MVI data at pri-
mary LR was not analyzed in our study. Similarly, Roayaie 
et al. (2009) reported that MVI could accurately predict 
the risk of recurrence and survival of patients after resec-
tion of HCC. Accordingly, the valuable MVI data might 
possibly predict tumor recurrence to some extent.
There were some main limitations to our study. First, 
there was a lack of intention-to-treat analysis. We did 
not have the adequate LR data on some patients because 
the hepatectomy was not conducted in our institution. 
Second, we conducted a single-center, retrospective 
study, which inevitably shared the limitations with the 
analyses of observational data. The extended period over 
which patients were selected for inclusion in the study 
was an additional limitation. With advances in surgical 
techniques, improved management after surgery, and 
more reasonable immunosuppressive therapy, the clini-
cal prognosis has changed since the period of selection 
Fig. 1 Kaplan–Meier survival estimates of RFS (a) and OS (b) between SLT and OLT
Table 3 Multivariate Cox regression analysis of  all LT 
patients
CI confidence interval, HR hazard ratio, AFP alpha-fetoprotein, MVI microscopic 
vascular invasion, TNM tumor node metastasis
HR 95 % CI for HR P value
Lower Upper
Recurrence-free survival
 AFP >400 ng/mL 1.581 1.109 2.255 0.011
 MVI 5.558 3.540 8.724 <0.001
 TNM staging 2.513 1.298 4.862 0.006
 Out of Milan criteria 2.945 1.946 4.457 <0.001
Overall survival
 MVI 3.798 2.659 5.425 <0.001
 TNM staging 1.499 1.104 2.034 0.009
 Out of Milan criteria 1.673 1.197 2.338 0.003
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of study subjects, resulting in heterogeneity among these 
patients.
Conclusion
In this study, we demonstrated that SLT has good OS 
post-transplantation and is a feasible alternative for HCC 
recurrence within Milan criteria. Organ shortages and 
tumor progression considered, SLT is an alternative strat-
egy for the treatment of patients with HCC.
Methods
Ethics approval
For this retrospective study formal consent is not 
required. This study was approved by the Institutional 
Review Board Liver Transplantation Surgery, Shanghai 
General Hospital, Shanghai, China under the guidelines 
of the Ethics Committee of the hospital, and the Declara-
tion of Helsinki (World Medical Association declaration 
of Helsinki. Recommendations guiding physicians in bio-
medical research involving human subjects 1997).
Patients
A retrospective review of the prospectively maintained 
database at Shanghai General Hospital, Shanghai Jiao 
Tong University School of Medicine, China, was con-
ducted. Three hundred seventy-one (331 males) HCC 
patients treated with LT between 2001 and 2011 were 
enrolled. The mean age of patients in our sample was 
48  years (range 16–65  years). All HCC diagnoses were 
based on histology results. The mean follow-up time was 
32.43  months (range 0.03–146.60  months). The follow-
up included alpha-fetoprotein and an ultrasound one to 
four times each month, and a thoracic-abdominal com-
puter tomography scan every 3.0–6.0  months during 
the first 2.0  years and annually thereafter. Patients with 
HCC fulfilling Hangzhou criteria (Xu et al. 2016) (tumour 
burden  ≤8  cm regardless of AFP and differentiation, or 
tumour burden  >8  cm but AFP  ≤400  ng/mL and well-
moderate differentiation) who received LT were included 
in the study. Although this study included patients using 
Hangzhou criteria rather than Milan criteria as previous 
studies (Fuks et al. 2012; Sala et  al. 2004; Ferrer-Fabrega 
et al. 2016), stratification analysis using Milan criteria was 
conducted. The exclusion criteria were (1) had undergone 
LT more than once; (2) had living donors or split-liver 
donors; (3) diagnosed with other malignancies in addi-
tion to HCC (cholangiocarcinoma, carcinoma of gallblad-
der, or mixed carcinoma); (4) had transplantation without 
recurrence after liver resection for HCC; (5) had tumor 
thrombosis of the main trunk of blood vessel (portal vein 
and hepatic vein); or (6) had missing pathology data.
Fig. 2 Kaplan–Meier survival estimates of RFS (a) and OS (b) between SLT and OLT within Milan criteria
Table 4 Multivariate logistic regression analysis of  risk 
factors for HCC recurrence
CI confidence interval, OR odds ratio, HCC hepatocellular carcinoma, MVI 
microscopic vascular invasion
OR 95 % CI for OR P value
Lower Upper
MVI 4.196 2.538 6.936 <0.001
Out of Milan criteria 2.704 1.643 4.451 <0.001
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Data collection
Patient baseline and clinical data comprising age, sex, 
blood type, pre-LT model for end-stage liver disease 
(MELD) score (Malinchoc et  al. 2000), pre-LT serum 
AFP level (stratification according to previous research) 
(Zheng et al. 2008), underlying liver disease, Child–Pugh 
status (Pugh et al. 1973), diameter of largest tumor, mul-
tinodular tumors, TNM staging (according to Interna-
tional Union Against Cancer/American Joint Committee 
on Cancer criteria), noncompliant with Milan criteria 
(Mazzaferro et al. 2008), histologic grade (differentiated 
[well differentiated  +  moderately differentiated] and 
poorly differentiated), MVI at LT, operative time, blood 
loss, packed red cell transfusion, reoperation, early post-
operative mortality (defined as death within the first 
90  days post-surgery), HCC recurrence, OS, and RFS 
were recorded. OS was defined as time from date of LT 
to death due to any cause. RFS was defined as the time 
from LT to the date of confirmed recurrence (Raza et al. 
2015).
Statistical analyses
All statistical analyses were performed using SPSS 
ver.19.0 statistical software (SPSS Inc., Chicago, 
IL, USA). Continuous data were expressed as the 
mean ± standard deviation (SD) or median (range), and 
discrete variables as frequencies. Categorical variables 
were compared using the Pearson’s χ2 test or Fisher’s 
exact test, whereas continuous variables were calcu-
lated with Student’s t test or Mann–Whitney test. Sur-
vival rates were assessed using Kaplan–Meier analysis 
and compared using the log-rank test. Recipient and 
tumor variables were calculated with univariate analysis 
and multivariate analysis for OS and RFS, respectively, 
using the Cox proportional hazard regression model. 
The logistic regression model was applied to investigate 
predictors of HCC recurrence after transplantation. The 
final models were determined by placing all variables 
with P < 0.05 from the univariate analysis into the mul-
tivariate Cox regression analysis and by using a forward 
stepwise method. Statistical significance was established 
as P < 0.05.
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